ClinicalTrials.gg
RecruitingNCT07855029Updated Oct 2, 2026

Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs)

An observational study in Chronic Hepatitis B, sponsored by Zhiliang Gao. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Zhiliang Gao · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
400
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 378 studies in Hepatitis B, Chronic with a site in China — 91 open to participants now, 112 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
59th of 101
400 · median 500
Started
2026
with 28 others
Observational
101 of 378
35 open now
Primary completion
2029-03
later than 103 of 111 live
Registered
369th of 378
by date

Among the 378 studies in Hepatitis B, Chronic with a site in China, this one is the 59th largest by planned enrollment of the 101 observational ones that give a count, is one of 29 that started in 2026, is one of 101 observational ones, reaches primary completion later than 103 of the 111 other live ones, and was the 369th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

91 of the 378 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

85 more — sign in →

All 91 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 378 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This single-center comparative cross-sectional study includes a prospective longitudinal follow-up cohort. At least 400 subjects from the "Everest Project" cohort will be enrolled into four groups: clinical-cure, non-cure, relapse, and healthy control. Data will be collected via online/offline questionnaires with internationally-standardized scales. This study aims to first systematically characterize the psychosocial value of chronic hepatitis B clinical cure, advance the shift from biomedical to biopsychosocial holistic health model, and provide scientific evidence for patient-management optimization and stigma-reduction public-health policy-making.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • Chronic Hepatitis B
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This observational cohort study enrolls 400 participants aged 18-65 years. Participants are recruited from the Zhufeng Project chronic hepatitis B cohort and frequency-matched healthy volunteers. Four groups are defined based on hepatitis B disease status: functional cure group, non-cured group, relapse group, and healthy control group. All participants provide written informed consent. Individuals with decompensated cirrhosis, HCC, other malignancies, HIV/HCV/HDV co-infection, severe uncontrolled psychiatric illness or severe comorbidities affecting quality of life are excluded.

Eligibility criteria

Inclusion Criteria:

  • Have participated in the "Zhufeng Project" with complete clinical data available.
  • Aged between 18 and 65 years old, inclusive.
  • Meet one of the following group-specific criteria:

Group 1: Functional Cure Group:

  • Subjects in the functional cure group are individuals with a well-documented history of chronic (HBsAg-positive for ≥6 months) who have achieved functional cure following antiviral therapy.
  • Inclusion criteria for this group:
  • All antiviral therapies have been discontinued, and the off-treatment follow-up period from treatment discontinuation to the screening visit is no less than 24 weeks;
  • Sustained post-treatment response during this period, operationally defined as confirmed HBsAg negativity (quantitative assay \<0.05 IU/mL) at or after Week 24 post-treatment discontinuation, plus persistently undetectable HBV DNA (\<10 IU/mL) by high-sensitivity PCR assay from treatment cessation through screening;
  • (ALT) level ≤ (ULN) at screening.

Group 2: Non-cured Group (active comparator group for this study):

  • The non-cured group serves as the active comparator and consists of participants with chronic hepatitis B receiving long-term effective antiviral treatment.
  • Eligibility criteria:
  • Receiving stable monotherapy with nucleos(t)ide analogs (NAs), with a total treatment duration of no less than 52 weeks. "Stable treatment" is defined as no regimen modification within the 24 weeks prior to screening;
  • Sustained virological suppression: documented HBV DNA below the lower limit of detection (\<20 IU/mL) on at least two occasions (interval >12 weeks) within the 24 weeks before screening;
  • Persistently positive HBsAg (>0.05 IU/mL) at screening;
  • ALT level ≤ upper limit of normal (ULN) at screening.

Group 3: Healthy Control Group:

  • The healthy control group provides normative baseline data for quality-of-life assessments. Eligible participants must be seronegative for all HBV serological markers (i.e., negative for HBsAg, anti-HBc, and HBV DNA), and have no known history of acute or chronic liver diseases.
  • Individuals with , severe cardiovascular or cerebrovascular diseases, psychiatric disorders, or other major systemic diseases that may independently affect quality of life are excluded. To minimize confounding from demographic variables, this group will be frequency-matched to the prior two groups by age (±5 years), sex, and educational level. All enrolled subjects must have ALT levels within the normal range at screening.

Group 4: Relapse Group:

  • Participants who previously fulfilled all eligibility criteria of the Functional Cure Group but developed virological relapse during off-treatment follow-up, defined as reversion from HBsAg-negative to HBsAg-positive status, and/or HBV DNA becoming detectable after being below the limit of detection.
  • Provide written for study participation.

Exclusion Criteria:

  • Presence of decompensated liver cirrhosis, hepatocellular carcinoma, or other malignant tumors.
  • Co-infection with , , or HDV.
  • Suffering from severe uncontrolled psychiatric disorders (e.g., schizophrenia, major depressive episode) or dementia.
  • Presence of other chronic diseases that severely impair quality of life (e.g., end-stage renal disease, severe heart failure, etc.).
  • Other conditions deemed ineligible for participation in this study by the investigator(s).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
400 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Clinical cure group

    Other: Observation-based data collection via patient-reported questionnaires

  • Non-cured group

    Other: Observation-based data collection via patient-reported questionnaires

  • Relapse group

    Other: Observation-based data collection via patient-reported questionnaires

  • Healthy control group

    Other: Observation-based data collection via patient-reported questionnaires

Interventions

  • OtherObservation-based data collection via patient-reported questionnaires

    No investigational intervention is assigned. Participants are categorized by their clinical hepatitis B status; patient-reported outcome questionnaires are administered for study assessments.

06

What researchers measure

Primary outcomes

  1. Hepatitis B Virus Infection-Related Stigma Scale (HBVISS) total score

    Social-psychological perceived stigma among participants from the "Zhufeng Project" cohort will be quantified using the HBVISS. Total scores will be compared across three subgroups: clinical cure group, non-cured group, and relapse group. Higher scores indicate higher perceived stigma.

    Time frame: Baseline (cross-sectional assessment at study enrollment)

Secondary outcomes

  1. PROMIS® GH-10 Global Physical Health (GPH) T-score

    T-score for global physical health, assessed using the PROMIS GH-10 instrument. Scores are compared across the four groups: clinical cure group, non-cured group, relapse group, and healthy control group.

    Time frame: Baseline

  2. PROMIS® GH-10 Global Mental Health (GMH) T-score

    T-score for global mental health, assessed using the PROMIS GH-10 instrument. Scores are compared across the four groups: clinical cure group, non-cured group, relapse group, and healthy control group.

    Time frame: Baseline

  3. Fear of Progression Questionnaire-Short Form (FoP-Q-SF) total score

    Total score of FoP-Q-SF, evaluating fear of disease progression among participants in non-cured group and relapse group.

    Time frame: Baseline

  4. Brief Illness Perception Questionnaire (B-IPQ) domain-specific scores

    Domain-level scores from B-IPQ for assessment of illness perception patterns in non-cured and relapse participants.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Mar 2029, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 2, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2032
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855029
Lead sponsor
Zhiliang Gao
Responsible party
Zhiliang Gao (Full Professor & Chief Physician, Third Affiliated Hospital, Sun Yat-Sen University) — Sponsor-investigator
First posted
Oct 2, 2026
Start date
Jul 1, 2026
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Oct 2, 2026

Study contacts

Zhiliang Gao, Ph.D
Contact
gaozhl@mail.sysu.edu.cn
18922102588
Zhiliang Gao
principal investigator · Third Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion